🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 46 of 55

  1. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    High-risk B-cell acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  2. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    Adult patients with refractory or relapsed follicular lymphoma

    phase 2 small molecule active

    1 trial

  3. TISLELIZUMAB

    Fondazione Telethon ETS

    Hodgkin lymphoma

    phase 2 small molecule active

    1 trial

  4. TKM-080301

    Arbutus Biopharma Corp

    Cancer

    phase 2 small molecule completed

    1 trial

  5. TKM-080301

    Arbutus Biopharma Corp

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  6. TL-895, TL-895

    Lacuna Pharma Pty Ltd

    B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  7. TNG260

    Tango Therapeutics

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. TNG348

    Tango Therapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  9. TNG456

    Tango Therapeutics

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. TNG462

    Tango Therapeutics

    Locally Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  11. TNG462, S095035 tablet 25mg, S095035 tablet 50mg, TNG462, TNG462

    The George Institute

    MTAP-deleted advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  12. TNG908

    Tango Therapeutics

    Locally Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  13. TNG908, TNG908, TNG908, TNG908, MIDAZOLAM

    Tango Therapeutics

    "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"

    phase 2 small molecule active

    1 trial

  14. TNO155, JDQ443, TNO155, VDT482/ BGB-A317, JDQ443, TNO155, TNO155

    Novartis Pharmaceuticals

    Advance solid tumors harboring the KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  15. TOCILIZUMAB, OBINUTUZUMAB, GLOFITAMAB, GLOFITAMAB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  16. TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, LEE011, TEMOZOLOMIDE, TEMOZOLOMIDE

    Novartis Pharmaceuticals

    Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)

    phase 2 small molecule active

    1 trial

  17. TPC induction chemotherapy

    Sun Yat-sen University

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  18. TPIV200

    Marker Therapeutics

    Ovarian Cancer

    phase 2 mab completed

    1 trial

  19. TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostatic Neoplasms, Castration-Resistant

    phase 2 small molecule active

    1 trial

  20. TQB3616 capsules

    Chia Tai Tianqing Pharmaceutical Group Co.,

    HR-positive, HER2-negative Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  21. TRASTUZUMAB DERUXTECAN

    Fondazione Telethon ETS

    metastatic HER2-positive breast cancer patients

    phase 2 small molecule active

    1 trial

  22. TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN

    Ningbo Cancer Hospital

    Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.

    phase 2 small molecule active

    1 trial

  23. TRASTUZUMAB EMTANSINE, Herceptin 150 mg powder for concentrate for solution for infusion, 89Zr-Trastuzumab_IJB

    The George Institute

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 small molecule active

    1 trial

  24. TRASTUZUMAB, FULVESTRANT, EXEMESTANE, PERTUZUMAB, PERTUZUMAB, TRASTUZUMAB, PERTUZUMAB, TUKYSA 150 mg film-coated tablets, LETROZOLE, TUKYSA 50 mg film-coated tablets, TRASTUZUMAB, ANASTROZOLE

    Ningbo Cancer Hospital

    HER2+ metastatic breast cancer with isolated brain progression

    phase 2 small molecule active

    1 trial

  25. TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, PERTUZUMAB, TRASTUZUMAB EMTANSINE

    Ningbo Cancer Hospital

    Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy

    phase 2 small molecule active

    1 trial

  26. TRC105

    United Therapeutics Europe Ltd

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  27. TREMELIMUMAB, DURVALUMAB

    The George Institute

    MSS and MSI colorectal and endometrial tumors

    phase 2 small molecule active

    1 trial

  28. TREMELIMUMAB, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., CISPLATINO Pfizer 50 mg/50 ml soluzione per infusione, DURVALUMAB

    Fondazione Telethon ETS

    locally advanced cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  29. TRETINOIN, gebasaxturev, MK-4280A, vibostolimab, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage IIIB or IIIC or IIID melanoma

    phase 2 small molecule active

    1 trial

  30. TRIPTORELIN, GONAPEPTYL 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée en seringues pré-remplies., LEUPRORELIN ACETATE, BAY 1841788, TRIPTORELIN, DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TRIPTORELIN, GOSERELIN ACETATE, LEUPRORELIN ACETATE, DEGARELIX, LEUPRORELIN ACETATE

    The George Institute

    Adult patients with intermediate unfavorable risk prostate cancer as per NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines Prostate Cancer. Version 2.2021)

    phase 2 small molecule active

    1 trial

  31. TRU-016 and bendamustine

    Aptevo Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule completed

    1 trial

  32. TRUQAP 200 mg film-coated tablets, TRUQAP 160 mg film-coated tablets

    AstraZeneca AB

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  33. TS-1 with cisplatin

    Hospital Authority, Hong Kong

    Recurrent Gastric Cancer

    phase 2 small molecule active

    1 trial

  34. TTI-101

    Tvardi Therapeutics

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  35. TTI-101

    Tvardi Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  36. TTX-MC138

    Transcode Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  37. TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets

    Ningbo Cancer Hospital

    Non-resectable locally advanced or metastatic HER2-positive breast cancer

    phase 2 small molecule active

    1 trial

  38. TYRA-300

    Tyra Biosciences

    Locally Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  39. Tabelecleucel

    Evidence Based Cataract Study Group

    Nasopharyngeal Carcinoma

    phase 2 mab terminated

    1 trial

  40. Tagraxofusp

    Stemline Therapeutics B.V.

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  41. Tak-228 & Tak-117

    Takeda

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  42. Talazoparib Tosylate

    BioMarin Pharmaceutical Australia Pty Ltd

    Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  43. Tarlatamab

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  44. Tarlatamab, TARLATAMAB, Tarlatamab, SILTUXIMAB

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  45. Tarlatamab, Tarlatamab

    The George Institute

    Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)

    phase 2 small molecule active

    1 trial

  46. Tarlatamab, Tarlatamab

    Partner Therapeutics Limited

    Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2

    phase 2 small molecule active

    1 trial

  47. Tas-102(Suyuan) combined with bevacizumab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  48. Tasigna 150 mg hard capsules, Scemblix 40 mg film-coated tablets

    Fondazione Telethon ETS

    BCR-ABL1+ Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.